Anticytokine therapies in systemic lupus erythematosus

被引：22

作者：

La Cava, Antonio ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Div Rheumatol, Dept Med, Los Angeles, CA 90095 USA

来源：

IMMUNOTHERAPY | 2010年 / 2卷 / 04期

关键词：

anticytokine therapy; clinical trial; cytokine; immunotherapy; systemic lupus erythematosus; TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; INDUCIBLE GENE-EXPRESSION; MRL-LPR/LPR MICE; RHEUMATOID-ARTHRITIS; DISEASE-ACTIVITY; MURINE LUPUS; FACTOR-ALPHA; MONOCLONAL-ANTIBODY; OPEN-LABEL;

D O I：

10.2217/IMT.10.29

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The dysfunctional immune response that characterizes systemic lupus erythematosus (SLE) associates with an unbalanced production of soluble mediators that are crucial in promoting and sustaining chronic inflammation. The successful use of biologics in several autoimmune diseases has led to studies in SLE aimed at contrasting the proinflammatory responses that contribute to tissue and organ damage in the disease. Several approaches have been developed and tested as potential therapeutic agents in SLE in preclinical studies and in clinical trials. This article provides an overview on antibody-based approaches in SLE that, although preliminary, have the potential to expand the current therapeutic possibilities in the disease.

引用

页码：575 / 582

页数：8

共 62 条

[1] INTERLEUKIN-1 AND INTERLEUKIN-6 ACTIVITIES ARE INCREASED IN THE CEREBROSPINAL-FLUID OF PATIENTS WITH CNS LUPUS-ERYTHEMATOSUS AND CORRELATE WITH LOCAL LATE T-CELL ACTIVATION MARKERS [J].

ALCOCERVARELA, J ;

ALEMANHOEY, D ;

ALARCONSEGOVIA, D .

LUPUS, 1992, 1 (02) :111-117

[2] Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus -: An open-label study [J].

Aringer, M ;

Graninger, WB ;

Steiner, GN ;

Smolen, JS .

ARTHRITIS AND RHEUMATISM, 2004, 50 (10) :3161-3169

[3] SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus [J].

Aringer, M ;

Smolen, JS .

ARTHRITIS RESEARCH & THERAPY, 2003, 5 (04) :172-177

[4] Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus [J].

Aringer, Martin ;

Steiner, Guenter ;

Graninger, Winfried B. ;

Hoefler, Elisabeth ;

Steiner, Carl W. ;

Smolen, Josef S. .

ARTHRITIS AND RHEUMATISM, 2007, 56 (01) :274-279

[5] Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus [J].

Baechler, EC ;

Batliwalla, FM ;

Karypis, G ;

Gaffney, PM ;

Ortmann, WA ;

Espe, KJ ;

Shark, KB ;

Grande, WJ ;

Hughes, KM ;

Kapur, V ;

Gregersen, PK ;

Behrens, TW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) :2610-2615

[6] Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice [J].

Balomenos, D ;

Rumold, R ;

Theofilopoulos, AN .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) :364-371

[7] Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies [J].

Bengtsson, AA ;

Sturfelt, G ;

Truedsson, L ;

Blomberg, J ;

Alm, G ;

Vallin, H ;

Rönnblom, L .

LUPUS, 2000, 9 (09) :664-671

[8]

BRENNAN DC, 1989, J IMMUNOL, V143, P3470

[9] The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus [J].

Cancro, Michael P. ;

D'Cruz, David P. ;

Khamashta, Munther A. .

JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (05) :1066-1073

[10] Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis [J].

Carlson, E ;

Rothfield, N .

ARTHRITIS AND RHEUMATISM, 2003, 48 (04) :1165-1166

← 1 2 3 4 5 6 7 →